Company intelligence / Profile preview

Vexim

Balma/Toulouse, Occitanie, Francevexim.cz ↗

Ownership: Private
Employees: ~60
Development stage: Other

Overview

Vexim developed and commercialized the SpineJack®, a minimally invasive implant for repairing fractured vertebrae and restoring spinal balance. The device was CE-marked and marketed across Europe, with clinical studies supporting its efficacy. In the US, it was investigational pending regulatory approval[1][5].

Therapeutic areas: RheumatologyNeurology
Modalities: Device (minimally invasive spinal implants)
Industry: Implantable Medical Devices

Partnerships

Truffle Capital (investor/shareholder)Banexi Venture Partners (investor/shareholder)

Beyond the preview

Go deeper on Vexim.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vexim.

Explore the full profile